Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma
Cancers · 26.06.2024 · 16 (13) · 2337
DOI: 10.3390/cancers16132337 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 26.06.2024. Verfasst von Paola Tacchetti und 4 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health, BolognAIL ODV.
Abstract (Originalsprache)
Bispecific antibodies (BsAbs) are artificially engineered antibodies that can bind simultaneously to the CD3 subunit within the T-cell receptor complex and an antigen on tumor cells, leading to T-cell activation and tumor cell killing. BsAbs against BCMA or GPRC5D have shown impressive clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM), with some agents having already received regulatory approval after the third (by the European Medicines Agency, EMA) or fourth (by the Food and Drug Administration, FDA) line of therapy; the results of early-phase clinical trials targeting FcRH5 are also promising. Overall, BsAbs as monotherapy correlated with an ORR that exceeded 60%, with a high CR rate ranging between 25% and 50% and a median PFS of around 1 year among patients with a median of 4–6 prior lines of therapy. The main toxicities include cytokine release syndrome, cytopenias, hypogammaglobulinemia, and infections; on-target off-tumor adverse events involving the skin, mucosa, hair, and nails may also occur with anti-GPRC5D BsAbs. Active research to increase their efficacy and improve their tolerance is still in progress, including combination therapies and application in earlier treatment lines and the development of novel agents. A better understanding of the mechanisms of resistance is a challenge and could lead to more personalized approaches.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
- Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.
ORCID-Profile: Katia Mancuso, Elena Zamagni, Michele Cavo
Förderung
- Italian Ministry of Health
- BolognAIL ODV
Zitieren
APA
Tacchetti, P., Barbato, S., Mancuso, K., Zamagni, E., & Cavo, M. (2024). Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma. Cancers, 16(13), 2337. https://doi.org/10.3390/cancers16132337
Vancouver
Tacchetti P, Barbato S, Mancuso K, Zamagni E, Cavo M. Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma. Cancers. 2024;16(13):2337. doi:10.3390/cancers16132337
BibTeX
@article{Tacchetti2024,
author = {Tacchetti, Paola and Barbato, Simona and Mancuso, Katia and Zamagni, Elena and Cavo, Michele},
title = {Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma},
journal = {Cancers},
year = {2024},
volume = {16},
number = {13},
pages = {2337},
doi = {10.3390/cancers16132337}
}
EUVIMED